Lokal fortgeschrittenes nichtkleinzelliges Lungenkarzinom: Radioimmuntherapie als neuer Standard?Locally advanced non-small cell lung cancer: radioimmunotherapy as new standard of care?

[1] Abuodeh Y(2016)Systematic review of case reports on the abscopal effect Curr Probl Cancer 40 25-37

[2] Venkat P(2017)Sequential tracking of PD-L1 expression and RAD50 induction in circulating tumor and stromal cells of lung cancer patients undergoing radiotherapy Clin Cancer Res 23 5948-5958

[3] Kim S(2018)Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC N Engl J Med 379 2342-2350

[4] Adams DL(2017)Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer N Engl J Med 377 1919-1929

[5] Adams DK(2015)Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study Lancet Oncol 16 187-199

[6] He J(2014)Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial Lancet Oncol 15 59-68

[7] Antonia SJ(2014)Intensity-modulated radiotherapy for lung cancer: Current status and future developments J Thorac Oncol 9 1598-1608

[8] Villegas A(2009)Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody Clin Cancer Res 15 5379-5388

[9] Daniel D(2014)Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade Cancer Res 74 5458-5468

[10] Antonia SJ(2018)Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179 J Clin Oncol 36 8500-8500

[1] Abuodeh Y(2016)Systematic review of case reports on the abscopal effect Curr Probl Cancer 40 25-37

[2] Venkat P(2017)Sequential tracking of PD-L1 expression and RAD50 induction in circulating tumor and stromal cells of lung cancer patients undergoing radiotherapy Clin Cancer Res 23 5948-5958

[3] Kim S(2018)Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC N Engl J Med 379 2342-2350

[4] Adams DL(2017)Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer N Engl J Med 377 1919-1929

[5] Adams DK(2015)Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study Lancet Oncol 16 187-199

[6] He J(2014)Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial Lancet Oncol 15 59-68

[7] Antonia SJ(2014)Intensity-modulated radiotherapy for lung cancer: Current status and future developments J Thorac Oncol 9 1598-1608

[8] Villegas A(2009)Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody Clin Cancer Res 15 5379-5388

[9] Daniel D(2014)Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade Cancer Res 74 5458-5468

[10] Antonia SJ(2018)Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179 J Clin Oncol 36 8500-8500